Last update Oct. 12, 2022
Amphetamine-related sympathomimetic used in the treatment of obesity. It is also used in certain serious drug-resistant epilepsies. (FDA 2020). Oral administration.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (low molecular weight and low percentage of plasma protein binding) makes it likely that significant amounts will pass into breast milk.
Its T1/2 of 20 hours would make it necessary to stop breastfeeding for about 140 hours after its administration.
Due to its frequent and serious cardiovascular toxicity it has been withdrawn as an anorectic from the market in most countries of the world. (FDA 2020, Kakkar 2015, Li 2011, AEMPS 2000)
There is good quality evidence that exclusive breastfeeding helps to regain pre-pregnancy weight earlier than if breastfeeding is partial (mixed) or there is no breastfeeding, and that prolonged breastfeeding helps maintain that loss and as well as body fat loss.(Jayasinghe 2021, Schalla 2017, López 2016, Jarlenski 2014, Sámano 2013, Neville 2014, Hatsu 2008, Dewey 2004, 2001 y 1993, Kramer 1993)
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM